Abstract Diosgenin 25R-spriost-5-en-3 -ol , is an important steroidal metabolite found in various plant species. e discovery of diosgenin as made it one of t e most researc ed and studied erbal product. Moreover, t ere is e cellent opportunity to address w et er diosgenin plays a role in c emoprevention versus t erapy, or bot . owever, rigorous e perimental based evidence in support of et nomedicine-derived notions would lead to t e development of products relevant to drug development. e ealt bene icial effects of diosgenin are furt er e tended to its potential role to treat ot er ailments suc as I and epatitis-infections as well as liver diseases. ere is little information regarding t e bioavailability, p armaco inetics and p armacodynamics of diosgenin in relation to its ealt bene icial effects. It as been reported to ave wide spectrum of biological properties t at contributes to several diseases in its role as a ealt bene icial p ytoc emical by citing new studies.
INTRODUCTION

Fig. 1: Diosgenin and its Pharmacological Effects (Kanika et al. 2012)
Diosgenin, a bioactive steroidal saponin from legumes and yams, ( en et al. 2015; Fuller et al. 2015; Miyos i et al. 2011; Raju and Me ta, 2009 is an anti-in lammatory, antidiabetic, antitumor, immunomodulatory, neuroprotective, estrogenic, vasodilatory compound, s in protective potency w ic also reduces blood lipid content and protects against isc emia induced neuronal damage ( ailleteau et al. 2008; en et al. 2011; en et al. 2015; Esfandiarei et al. 2011; Gong et al. 2010; Lepage et al. 2011; Rog ani-De ordi et al. 2015; Li et al. 2010; Li et al. 2015 owever, a limited number of studies ave been performed on t e reproductive effect of diosgenin on female; t e study will elucidates t e ability and molecular mec anisms of diosgenin. is review will provide t e bene icial role of diosgenin against metabolic diseases and p armacological effects ( Fig. 1 . 
BIOLOGICAL ACTIVITIES OF DIOSGENIN
Diosgenin, a steroid saponin, is a major bioactive constituent of various edible pulses and roots, found in plants suc as Dioscorea bulbifera, Dioscorea alata, Dioscorea trinervia. Dioscorea deltoidea, Dioscorea oppositifolia, Solanum xanthocarpum as well as in t e seeds of fenugree (Trigonella foenum-graecum ( ani a et al. 2012 . In t e p armaceutical industry, diosgenin is a well-nown precursor in t e manufacture of synt etic steroidal drugs (Raju and Me ta 2009 . Diosgenin possess a wide range of ealt bene icial properties, w ic as been used in traditional medicine as an anti yperc olesterolemia, anti yperglycemia and antidiabetes agent. ver t e past decade, a series of preclinical and mec anistic studies ave s owed t at diosgenin could in ibit proliferation and induce apoptosis in a wide variety of tumor cells, including osteosarcoma, colon carcinoma, leu emia, epatoma and breast carcinoma ( iang et al. 2007; Li et al. 2010; Moalic et al. 2001 . e anti-tumor mec anisms of diosgenin as been demonstrated via modulation of multiple cell signaling events involving critical molecular candidates associated wit growt , differentiation, apoptosis and oncogenesis ( en et al. 2011 . erefore, t ese preclinical and mec anistic indings strongly implicate t at diosgenin may possess t e cancer c emot erapeutic potential as a novel, multi target-based t erapeutic agent against many cancer types ( Fig. 2 and 3 . 
EP-2 C C
Diosgenin in ibited ep2 cell growt . e I 50 cytoto ic dose of diosgenin en ances lipid pero idation status and decreases antio idant levels in ep2 cells, t ereby decreasing cell malignancy or transformation and in ibits tumor promotion. Diosgenin is a potent in ibitor of ep2 carcinoma cells, by growt in ibition, en anced R S generation and lipid pero idation and decreased antio idant activity in ep2 cells w ic s ows t at diosgenin possess proo idant properties (Mirunalini et al. 2011 .
P C C
e effect and underlying mec anism of diosgenin on DU145 uman prostate cancer cells were cultured in vitro and cell proliferation was detected by a 3-(4,5-dimet ylt iazol-2-yl -2,5-dip enyltetrazolium bromide assay and apoptosis was detected by low cytometry. e mec anism underlying t e effect of diosgenin on DU145 cells, western blotting was performed to evaluate t e involvement of t e p osp atidylinositol 3 inase ( I3 protein inase (A t mammalian target of rapamycin (m R signaling pat way. e association between apoptosis and autop agy was investigated; DU145 cells were cultured wit diosgenin and 3-met yladenine. oec st 33342 propidium iodide double staining was performed to detect apoptosis, and reverse transcription-uantitative polymerase c ain reaction was used to analyze mR A e pression levels of eclin 1 and -cell lymp oma 2. e mec anism underlying t e activation of apoptosis and autop agy may be associated wit t e in ibition of t e I3 A t m R signaling pat way. In addition, t e in ibition of autop agy mediated by diosgenin increases apoptosis and, t us, increases t e t erapeutic effect. e combination of diosgenin wit an autop agy in ibitor may be an effective strategy to increase t e antitumor effect of diosgenin ( ie et al. 2016 .
A -P E
Diosgenin as been used on four uman cancer cell lines viz. L-100 (breast , A549 (lung , -29 (colon and -116 (colon using 3-(4,5-dimet ylt iazolyl-2 -2,5-dip enyltetrazoliumbromide (M assay. Among t e synt esized analogues, Dgn-1 bearing a simple p enyl R moiety attac ed via triazole to t e parent molecule was identi ied as t e most potent analogue against A549 cancer cell line aving I 50 of 5.54 lM, better t an t e positive 9 control ( EZ-235 . Dgn-2 and Dgn-5 bearing o-nitrop enyl and o-cyanop enyl R moieties respectively, displayed impressive anti-proliferative activity against all t e tested uman cancer cell lines wit I 50 values ranging from 5.77 to 9.44 lM.
e structure-activity relations ip (SAR revealed t at t e analogues wit simple p enyl R moiety or electron wit drawing ort o substituted R moieties seem to ave bene icial impact on t e anti-proliferative activity (Masood et al. 2017 .
C R F
ronic renal failure ( RF in rats was induced by feeding rats wit diet containing 0.75 adenine for 5 wee s. Diosgenin was given orally at a dose of 40 mg g body weig t (bw of animal eac and every day. It as s own t at adenine containing diet induced RF in rats elevates liver o idative stress by suppressing t e activity of enzymatic antio idant system, increased lipid pero idation, and macromolecular structural alterations. reatment of diosgenin 40 mg g bw of rat signi icantly restores t e enzymatic antio idant system and reduces t e lipid pero idation level. Moreover, based on t e F IR (fourier transform infrared spectroscopy study, it was con irmed t at diosgenin administration signi icantly protected t e macromolecular c anges including, t e protein structural damage t at occurred in liver. Diosgenin as proved t e epato protective action t roug antio idant and molecular protection effect in RF condition ( eganat an et al. 2013 . 
N E
R S
Effect of yam and diosgenin on t e calpain isoform e pression in ovariectomized rats was administered for 8 wee s. In t is study, control group was signi icantly ig er t an t ose in t e ovariectomized group. In contrast, t ere was no signi icant difference in t e e pression of mu-and m-calpain mR As among t e different diosgenin groups (Moalic et al. 2001 . Diosgenin w en administered subcutaneous (sc at t e dose levels of 20 and 40 mg g body weig t for a period of 15 days stimulated t e growt of mammary epit elium. It s ows increase in D A content, number of ducts and appearance of terminal endbuds. ere was a signi icant increase in t e mammary development scores in t e presence of diosgenin. oncomitant treatment of estrogen and diosgenin s owed augmentation of estrogenic effect of diosgenin especially at t e ig er dose level (40 mg g body wt . Diosgenin s owed a lac of progesterogenic action even in t e presence of e ogenous estrogen ( en et al. 2011 . An effect of diosgenin on estrogenic activity was investigated. In t is study, diosgenin did not affect t e uterine wet weig t, epit elium eig t, volume densities of endometrium, endometrial epit elia, number of endometrial glands, or istological appearance of vaginal epit elia. It is concluded t at diosgenin, at doses of 20-200 mg g, did not act as an estrogen agonist in t e immature rat uterotrop ic assay (Medigovic et al. 2014 .
C F
Diosgenin may in ibit ig glucose-induced renal tubular ibrosis; studies ave focused on t e effects of diosgenin on cardiac ibrosis. its aimed to e plore t e effects of diosgenin on angiotensin II (Ang II -induced e tracellular matri (E M remodeling, and its possible mec anism in rat Fs.
Fs were pre-incubated wit diosgenin (1, 5 and 10 M for 24 and were t en stimulated wit Ang II (100 nM for 24
. ell proliferation was estimated using t e M S assay. e e pression levels of -SMA, ibronectin, collagen I, GF-1, in addition to p osp orylation of Smad3 were detected by western blotting. e results demonstrated t at diosgenin in ibited Ang II-induced cardiac ibrosis ( Fs proliferation and t e differentiation of Fs to myo ibroblasts. In addition, diosgenin was able to in ibit Ang II-induced E M e pression in rat Fs. Furt ermore, diosgenin in ibited Ang II-induced e pression of transforming growt factor-1 ( GF-1 and Smad3 p osp orylation in Fs. a en toget er, t ese results suggest t at diosgenin may in ibit Ang II-induced E M remodeling by suppressing t e GF-1 Smad3 signaling pat way in rat Fs.
erefore, diosgenin may possess t erapeutic potential for t e treatment of cardiac ibrosis (Z ou et al. 2007 (Fig. 4 .
G D
o e amine t e effect of Diosgenin (DSG on Gestational diabetes (GD and to investigate t e possible mec anism in 57 L s -Lepdb (db mice. It was found t at DSG could remar ably ameliorated GD in pregnant db mice, as re lected by t e improvement of glucose and insulin intolerance, and t e decrease of fasting blood glucose and insulin level and t e increase of epatic glycogen content.
Fig. 4: Cardiac Fibrosis
e results s owed t at DSG could in ibit o idative stress in pregnant db mice, as evidenced by decrease of t iobarbituric acid reactive substances ( ARS content, increase of glutat ione (GS level and supero ide dismutase (S D and catalase ( A activities. DSG could also attenuate t e abnormal c anges of lipid pro iles, including , G and LDL, in pregnant db mice. e increase of t e e pression of sterol regulatory element-binding transcription factor-1 (SRE -1 and its target genes, including fatty acid synt ase (FAS , stearoyl-oA desaturase-1 (S D-1 , and acetyl coenzyme A carbo ylase (A , was in ibited by DSG in pregnant db mice. Moreover, overe pression of SRE -1 by L -SRE -1 injection could mar edly in ibit t e protective effect of DSG against disorder of glucose and lipid metabolism and o idative stress in GD mice. e data demonstrated t at SRE -1 may be of major target of DSG t at mediated its anti-diabetic activities in GD. e data provide novel insig ts into t e biological activities of DSG and pave way for t e investigation of t e anti-diabetic activities against GD (S aofang et al. 2016 .
B G L
Diosgenin signi icantly decreased plasma glucose in streptozotocin-induced diabetic rats by comparison to t e diabetic controls suggesting its anti-diabetic properties. ese results were furt er strengt ened by t e fact t at several epatic rate-limiting enzymes commonly involved in glucose metabolism altered in t e diabetic state were normalized by treatment wit diosgenin (McAnuff et al. 2005 . C C ell cycle analysis s owed t at diosgenin caused G2 M arrest independently of p53. e levels of cyclin 1 and p21 ip1 Waf1 were decreased, w ereas cdc2 levels were increased. Subse uent apoptosis was demonstrated wit t e dramatic activation of caspase-3. A dramatic decline in intracellular a2 concentration was observed as an initiating event in t e process of cell cycle arrest and apoptosis, w ic was followed by t e yperpolarization and depolarization ofMM . Generation of R S was observed in t e progression of apoptosis. e antiapoptotic cl-2 and cl-L proteins were down regulated, w ereas t e pro apoptotic a was up regulated. Diosgenin in ibits 562 cell proliferation via cell cycle G2 M arrest and apoptosis, wit disruption of a2 omeostasis and mitoc ondrial dysfunction playing vital roles (Liu et al. 2005 . Diosgenin induced apoptosis is caspase-3 dependent wit a fall of mitoc ondrial membrane potential, nuclear localization of AIF and poly (AD -ribose polymerase cleavage. Diosgenin treatment also induces p53 activation and cell cycle arrest in t e different cell lines studied ( ecile et al. 2004 .
P D C C
ral ingestion of diosgenin in t e diet for 8 wee s led to a dose-dependent increase in t e ydro yproline ( yp content as collagen content of s in. In proliferating of primary cultured ibroblasts, diosgenin treatment led to a decrease of adenosine 5 -trip osp ate content indicating decrease of t e cell number. In t e cells reac ed to con luent, alt oug increase of yp content in t e control indicating progress of ibroblasts differentiation were observed, t e content of yp remained unc anged wit dios treatment. Finally, addition of dios led to a decrease t e -tubulin and c-fos mR A e pressions relating to t e cell cycle. It is concluded t at Dios can improve s in collagen content by s ifting t e dynamics of t e ibroblasts from proliferation to differentiation via cell cycle arrest ( arata e et al. 2017 .
A -A E
Diosgenin administration increased t e number of Fo p3 reg cells co-e pressing 1mar ers, including R5, R3, IF -and -bet in t e intestine and en anced populations of Fo p3 IFand Fo p3 -bet cells t at e pressed t e regulatory cyto ineIL-10 in t e eyer s patc es. Diosgenin also augmented t e intestinal e pression of R3, L3, and L10. oncordantly, diosgenin increased t e number of R3 Fo p3 IL10 cells in t e eyer s patc es.
is study demonstrated t e en anced induction of 1-li e reg cells in allergic mice treated wit diosgenin, providing evidence to suggest a role for 1-li e regcellsin diosgenin-mediated anti-allergic effects against 2-type allergy ( ung-siung et al. 2017 .
C M L C
Autop agy induction was demonstrated by e amination of autop agic lu including autop ago-somes accumulation, autop agosome-lysosome fusion and degradation of autop agosomes. Moreover, bloc ing autop agy wit in ibitor c loro uine ( and 3-met yladenine (3-MA , en anced diosgenin-induced apoptosis, indicating t e protective effect of autop agy in diosgenin-treatedc ronic myeloid leu emia ( ML cells. Furt er study suggested t at diosgenin-induced autop agy and cytoto icity were accompanied by reactive o ygen species (R S generation and mammalian target of rapamycin (m R signaling pat way in ibition. N-acetyl-L-cysteine ( A administration, a scavenger agent of R S, could down-regulate diosgenin-induced autop agy via reversion of m R pat way in ibition.
ese results indicate t at diosgenin obviously generates R S and t is 12 o idative pressure not only produces cytoto ic effect on ML cells but also induces autop agy. Autop agy functions as a cytoprotective mec anism to overcome cytoto icity of diosgenin in tumor cells and in ibition of autop agy can en ance t e anti-ML activity of diosgenin (S ans an et al. 2016 .
M P E
and Dioscorea opposita are two traditional inese medicines widely used in ina for treating diabetes mellitus and its complications, suc as diabetic cardiomyopat y. Morroniside (Mor of and diosgenin (Dio of Dioscorea opposita formed an innovative formula named M D. e aims of t e present study were to investigate myocardial protective effect of M D on diabetic cardiomyopat y (D M t roug t e in ibition of e pression levels of caspase-3 protein, and identify t e advantage of M D compared wit Mor, Dio, and t e positive drug metformin (Met . It is detected cell viability, cell apoptosis, intracellular reactive o ygen species (R S levels, and t e e pression levels of cl-2, a , and caspase-3 protein in rat cardiomyocytes. In result, Mor, Dio, and M D increased cell viability, in ibited cell apoptosis and decreased R S levels. Additionally, t e e pression of a and cl-2 protein was modulated and t e e pression levels of caspase-3 protein were mar edly decreased. Among t e treatment groups, M D produced t e most prominent effects. In conclusion, t e result s owed for t e irst time t at Mor, Dio, and M D prevented ig glucose ( G -induced myocardial injury by reducing o idative stress and apoptosis in rat cardiomyocytes. Among all t e groups, M D produced t e strongest effect, w ile Mor and Dio produced wea er effects (Wen-ia et al. 2017 .
A L I
Diosgenin signi icantly suppressed t e p osp orylation of lung F-p50 p65 and MA p38 in lipopolysacc aride (L S -induced acute lung injury (ALI in mice, w en given orally at doses of 0.1, 1.0 and 10 mg g 1 prior to L S c allenge (30 mg g, intravenous injection . Moreover, diosgenin attenuated t e lung istopat ological c anges suc as pulmonary edema, coagulation and in iltration of in lammatory cells. In addition, diosgenin signi icantly decreased t e lung wet to dry weig t (W D ratio and nitrite nitrate content at t ree doses, and also mar edly in ibited L S-induced body temperature decrease and nitrite nitrate elevation in plasma. esides, diosgenin could signi icantly suppress activation of Fp65 p50, p38 and e pression of inducible nitric o ide synt ase (i S in L S-induced -1 cells. ese indings indicate t e potential application of diosgenin for ALI treatment (Mengyu et al. 2013 .
M P
Effects of dietary diosgenin on indomet acin induced intestinal in lammation and alterations in bile secretion in rats were investigated. Diosgenin pretreatment signi icantly in ibited weig t and food inta e decreases and intestinal in lammation. Diosgenin signi icantly increased biliary c olesterol output and prevented t e decreases in bile low, bile acid output, and biliary alp a-muric olic acid and t e increases in biliary yodeo yc olic acid, deo yc olic acid, and ydrop obicity inde of bile ( amada et al. 1997 . Effect of diosgenin in biliary secretion and intestinal absorption of c olesterol in diosgenin stimulated fecal c olesterol e cretion in wild type and 1L1-noc out (L1 mice were investigated. Fecal c olesterol e cretion increased in diosgenin-fed W andL1 mice. In an in vitro assay, diosgenin was unable to bloc 1L1-dependent c olesterol upta e ( emel et al. 2009 . 
References
Dyslipidemia/ obesity olesterollowering olesterol-fed rats a y e n a n d Dvorni (1979 uarez-ropeza et al. 1987 Son et al. 2007 olesterolfed ic en a y e n a n d Dvorni (1979 olesterolfed rabbit a y e n a n d Recently, some researc ers used a single enzyme (suc as cellulase and t eamylase combined wit acid ydrolysis to treat inese yam (Dioscorea opposita unb material, demonstrating t at about 70 diosgenin can be e tracted from t e material. owever, t e activity of enzyme gradually reduces owing to t e c ange of catalysis environment, so t at t e catalysis ef iciency of enzyme will also reduce. A focused microwave-assisted e traction met od was developed for t e e traction of diosgenin from Fenugree (Trigonella foenum-graecum ( aufmann et al. 2007 .
A T D
Gas c romatograp y-mass spectrometry (G -MS met od to determine t e content of diosgenin in rats as been reported. For uanti ication; a single-ion monitoring (SIM mode was used; t e limit of uanti ication (L was 13 ng mL, and separation time was 18 min. A sensitive and speci ic electro spray ionization li uid c romatograp ytandem mass spectrometry met od was developed to detect diosgenin in t e plasma of normal and yperlipidemic rats.
is tec ni ue can be used successfully to study p armaco inetics in rats after oral administration of diosgenin and would be bene icial for t e clinical use of diosgenin ( u et al. 2009 .
DISCUSSION
Several medicinal plants ave been used as dietary adjunct and in t e treatment of numerous diseases wit out proper nowledge of t eir function. nly a few erbs and bioactive c emical moiety ave attracted t e interest of scientists and ave been put forward for investigations. owever, t e p armacologic actions of t ese compounds need to be evaluated in studies involving umans to justify t e use of t ese plants or t eir active principles for t e treatment of various disorders. erefore, t ere is a need of more welldocumented clinical trials and more laboratory wor to justify t eir p armacological actions and to icity for safe and effective treatment. Diosgenin w ic , as per, mentioned above may ave all t ese actions and could prove to be promising in t e treatment of various complications especially against cancer in t e near future. Despite t e great interest in t e development of new drugs to prevent t e burden of omplications associated wit t is disease and raised interest in t e scienti ic community to evaluate eit er raw or isolated natural products in e perimental studies, few of t em was tested in umans. ased on t e available data it was concluded t at t is bioactive compound ave various type of activity and bene icial effect against microorganism, in lammation, cardiovascular disease, blood disorder, cerebral disorder, immune system, o idative stress, reproductive and cancer c emot erapy. owever t eir speci ic effects on cancer disease give valuable role for t e treatment of various type of cancerous disease. Alt oug p ytot erapy continues to be used in several countries, few plants ave received scienti ic or medical scrutinity ( ani a et al. 2012 .
CONCLUSION
Diosgenin and diosgenin-containing products are emerging in t e mar et and are being promoted as natural ealt products. e scienti ic nowledge in t is area is limited and ence e tensive pre-clinical and clinical researc s ould be carried out prior to advocating t e safe and ef icacious use of diosgenin and diosgenin-ric plant e tracts against t e prevention and control of diseases. ence, t e review was prompted by t e urgent re uirement for natural, safe and effective against many diseases. 
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